Histone deacetylase inhibitors: Apoptotic effects and clinical implications (review)

International Journal of Oncology

Volumn 33, Issue 4, 2008, Pages 637-646

  Emanuele, Sonia ^a   Lauricella, Marianna ^a   Tesoriere, Giovanni ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Acetylation; Apoptosis; Epigenetics; Histone deacetylase inhibitors; Tumor cells

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 4 N ACETYLDINALINE; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; BELINOSTAT; BUTYRIC ACID; DEPSIPEPTIDE; DEPUDECIN; DIMETHYL SULFOXIDE; DNA TOPOISOMERASE INHIBITOR; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; IMATINIB; ITF 2357; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; OXAMFLATIN; PANOBINOSTAT; PHENYLACETIC ACID; PIVALOYLOXYMETHYL BUTYRATE; PROTEASOME INHIBITOR; PYROXAMIDE; ROMIDEPSIN; TRAPOXIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CHROMATIN; CLINICAL TRIAL; DOWN REGULATION; DRUG ACETYLATION; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; ENZYME MODIFICATION; EPIGENETICS; GENE EXPRESSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STRUCTURE ANALYSIS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CHROMATIN; DEPSIPEPTIDES; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MODELS, BIOLOGICAL; MODELS, CHEMICAL; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY;

EID: 54049093249     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_00000049     Document Type: Review

References (130)

1. Reik W: Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 447: 425-432, 2007.
2. Miremadi A, Oestergaard MZ, Pharoah PD and Caldas C: Cancer genetics of epigenetic genes. Hum Mol Genet 16 (Spec 1): R28-R49, 2007.
3. Kurdistani SK: Historic modifications as markers of cancer prognosis: a cellular view. Br J Cancer 97: 1-5, 2007.
4. Palii SS and Robertson KD: Epigenetic control of tumor suppression. Crit Rev Eukaryot Gene Expr 17: 295-316, 2007.
5. Lettini AA, Guidoboni M, Fonsatti E, Anzalone L, Cortini E and Maio M: Epigenetic remodelling of DNA in cancer. Histol Histopathol 22: 1413-1424, 2007.
6. Santos-Rosa H and Caldas C: Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer 41: 2381-2402, 2005.
7. Schneider-Stock R and Ocker M: Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors. IDrugs 10: 557-561, 2007.
8. Jenuwein T and Allis CD: Translating the histone code. Science 293: 1074-1080, 2001.
9. Mello JA and Almouzni G: The ins and outs of nucleosome assembly. Curr Opin Genet Dev 11: 136-141, 2001.
10. Gray SG and Ekstrom TJ: The human histone deacetylase family. Exp Cell Res 262: 75-83, 2001.
11. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA and Anderson KC: Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 101: 540-545, 2004.
12. Mahlknecht U and Hoelzer D: Histone acetylation modifiers in the pathogenesis of malignant disease. Mol Med 6: 623-644, 2000.
13. Bryan EJ, Jokubaitis VJ, Chamberlain NL Baxter SW, Dawson E, Choong DY and Campbell IG: Mutation analysis of EP300 in colon, breast and ovarian carcinomas. Int J Cancer 102: 137-141, 2002.
14. Marks PA, Richon VM and Rifkind RA: Histone deacetylase inhibitors: inducers of differentiation or apoptosis in transformed cells. J Natl Cancer Inst 92: 1210-1216, 2000.
15. Armeanu S, Pathil A, Venturelli S, Mascagni P, Weiss TS, Gottlicher M, Gregor M, Lauer UM and Bitzer, M: Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J Hepatol 42: 210-217, 2005.
16. Somech R, Izraeli S and J Simon A: Histone deacetylase inhibitors: a new tool to treat cancer. Cancer Treat Rev 30: 461-472, 2004.
17. Richon VM, Sandhoff TW, Ritking RA and Marks PA: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97: 10004-10019, 2000.
18. Bi G and Jiang G: The molecular mechanism of HDAC inhibitors in anticancer effects. Cell Mol Immunol 3: 285-290, 2006.
19. Warrener R, Beamish H, Burgess A, Waterhouse NJ, Giles N, Fairlie DP and Gabrielli B: Tumor cell-specific cytotoxicity by targeting cell cycle checkpoints FASEB J 17: 1550-1552, 2003.
20. Peart MJ, Smyth GK, van Laar RK, Bowtell, DD, Richon VM, Marks PA, Holloway AJ and Johnstone RW: Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 102: 3697-3702, 2005.
21. Lin H, Chen C, Shuan L, Weng J and Chen C: Targeting histone deacetylase in cancer therapy. Med Res Rev: 1-17, 2006.
22. Liu T, Kuljaca S, Tee A and Marshall GM: Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 32: 157-165, 2006.
23. Yang QC, Zeng BF, Shi ZM, Dong Y, Jiang ZM, Huang J, Lv YM, Yang CX and Liu YW: Inhibition of hypoxia-induced angiogenesis by trichostatin A via suppression of HIF-1a activity in human osteosarcoma. J Exp Clin Cancer Res 25: 593-599, 2006.
24. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, Moon EJ, Kim HS, Lee SK, Chung HY, Kim CW and Kim KW: Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7: 437-443, 2001.
25. Lin KT, Yeh SH, Chen DS, Chen PJ and Jou YS: Epigenetic activation of alpha4, beta2 and beta6 integrins involved in cell migration in trichostatin A-treated Hep3B cells. J Biomed Sci 12: 803-813, 2005.
26. Klisovic DD, Klisovic MI, Effron D, Liu S, Marcucci G and Katz SE: Depsipeptide inhibits migration of primary and metastatic uveal melanoma cell lines in vitro: a potential strategy for uveal melanoma. Melanoma Res 15: 147-153, 2005.
27. Whetstine JR, Ceron J, Ladd B, Dufourcq P, Reinke V and Shi Y: Regulation of tissue-specific and extracellular matrix-related genes by a class 1 histone deacetylase. Mol Cell 18: 483-490, 2005.
28. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y and Carrier F: Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63: 7291-7300, 2003.
29. Ocker M, Alajati A, Ganslmayer M, Zopf S, Luders M, Neureiter D, Hahn EG, et al: The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J Cancer Res Clin Oncol 131: 385-394, 2005.
30. Dey P: Chromatin remodeling, cancer and chemotherapy. Curr Med Chem 13: 2909-2919, 2006.
31. Matsushita H, Scaglioni PP, Bhaumik M, Rego EM, Cai LF, Majid SM, Miyachi H, Kakizuka A, Miller WH Jr and Pandolfi PP: In vivo analysis of the role of aberrant histone deacetylase recruitment and RAR alpha blockade in the pathogenesis of acute promyelocytic leukemia J Exp Med 203: 821-828, 2006.
32. Jeyakumar M, Liu XF, Erdjument-Bromage H, Tempst P and Bagchi MK: Phosphorylation of thyroid hormone receptor-associated nuclear receptor corepressor holocomplex by the DNA-dependent protein kinase enhances its histone deacetylase activity. J Biol Chem 282: 9312-9322, 2007.
33. Ropero S and Esteller M: The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 1: 19-25, 2007.
34. Ryan CM, Harries JC, Kindle KB, Collins HM and Heery DM: Functional interaction of CREB binding protein (CBP) with nuclear transport proteins and modulation by HDAC inhibitors. Cell Cycle 5: 2146-2152, 2006.
35. Marmorstein R and Roth SY: Histone acetyltransferases: function, structure and catalysis. Curr Opin Genet Dev 11: 155-161, 2001.
36. Chérasse Y, Maurin AC, Chaveroux C, Jousse C, Carraro V, Parry L, Deval C, Chambon C, Fafournoux P and Bruhat A: The p300/CBP-associated factor (PCAF) is a cofactor of ATF4 for amino acid-regulated transcription of CHOP. Nucleic Acids Res 35: 5954-5965, 2007.
37. Roelfsema JH and Peters DJ: Rubinstein-Taybi syndrome: clinical and molecular overview. Expert Rev Mol Med 20: 1-16, 2007.
38. Tillinghast GW, Partee J, Albert P, Kelley JM, Burtow KH and Kelly K: Analysis of genetic stability at the EP300 and CREBBP loci in a panel of cancer cell lines. Genes Chromosomes Cancer 37: 121-131, 2003.
39. Zhang C, Li K, Wei L, Li Z, Yu P, Teng L, Wu K and Zhu J: p300 expression repression by hypermethylation associated with tumour invasion and metastasis in oesophageal squamous cell carcinoma. J Clin Pathol 60: 1249-1253, 2007.
40. Horiuchi J, Silverman N, Marcus GA and Guarente L: ADA3, a putative transcriptional adaptor, consists of two separable domains and interacts with ADA2 and GCN5 in a trimeric complex. Mol Cell Biol 15: 1203-1209, 1995.
41. Baker SP and Grant PA: The SAGA continues: expanding the cellular role of a transcriptional co-activator complex. Oncogene 26: 5329-5340, 2007.
42. Nagy Z and Tora L: Distinct GCN5/PCAF-containing complexes function as co-activators and are involved in transcription factor and global histone acetylation. Oncogene 26: 5341-5357, 2007.
43. Candau R, Moore PA, Wang L, Barlev N, Ying CY, Rosen CA and Berger SL: Identification of human proteins functionally conserved with the yeast putative adaptors ADA2 and GCN5. Mol Cell Biol 16: 593-602, 1996.
44. Dilworth FJ, Seaver KJ, Fishburn AL, Htet SL and Tapscott SJ: In vitro transcription system delineates the distinct roles of the coactivators pCAF and p300 during MyoD/E47-dependent transactivation. Proc Natl Acad Sci USA 101: 11593-11598, 2004.
45. Marmorstein R: Structure of histone acetyltransferases. J Mol Biol 311: 433-444, 2001.
46. Clarke AS, Samal E and Pillus L: Distinct roles for the essential MYST family HAT Esalp in transcriptional silencing. Mol Biol Cell 17: 1744-1757, 2006.
47. Clarke AS, Lowell JE, Jacobson SJ and Pillus L: Esa1p is an essential histone acetyltransferase required for cell cycle progression 1. Mol Cell Biol 19: 2515-2526, 1999.
48. Kamine J, Elangovan B, Subramanian T, Coleman D and Chinnadurai G: Identification of a cellular protein that specifically interacts with the essential cysteine region of the HIV-1 Tat transactivator. Virology 216: 357-366, 1996.
49. Jacobson RH, Ladurner AG, King DS and Tjian R: Structure and function of a human TAFII250 double bromodomain module. Science 288: 1422-1425, 2000.
50. Gegonne A, Weissman JD and Singer DS: TAFII55 binding to TAFII250 inhibits its acetyltransferase activity. Proc Natl Acad Sci USA 98: 12432-12437, 2001.
51. Parthun MR: Hat1: the emerging cellular roles of a type B histone acetyltransferase. Oncogene 26: 5319-5328, 2007.
52. Yang T, Fu M, Pestell R and Sauve AA: SIRT1 and endocrine signaling. Trends Endocrinol Metab 17: 186-191, 2006.
53. Defossez P, Lin S and McNabb DS: Sound silencing: the Sir2 protein and cellular senescence. Bioessays 23: 327-332, 2001.
54. Whittle JR, Powell MJ, Popov VM, Shirley LA, Wang C and Pestell RG: Sirtuins, nuclear hormone receptor acetylation and transcriptional regulation. Trends Endocrinol Metab 18: 356-364, 2007.
55. Marks PA, Richon VM and Rifkind RA: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202, 2001.
56. Wang C, Fu M, Mani S, Wadler S, Senderowicz AM and Pestell RG: Histone acetylation and the cell cycle in cancer. Front Biosci 6: D610-D629, 2001.
57. Conley BA, Wright JJ and Kummar S: Targeting epigenetic abnormalities with histone deacetylase inhibitors. Cancer 15: 832-840, 2006.
58. Amann JM, Nip J, Strom DK, et al: ETO, a target of t(8;21) in acute leukaemia, makes distinct contacts with multiple histone deacetylases and binds mSin3 through its oligodimerization domain. Mol Cell Biol 21: 6470-6483, 2001.
59. Ferrara FF, Fazi F, Bianchini A, Padula F, Gelmetti V, Minucci S, Mancini M, Pelicci PG, Lo Coco F and Nervi C: Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 61: 2-7, 2001.
60. Cimino G, Lo-Coco F, Fenu S, Travaglini L, Finolezzi E, Mancini M, Nanni M, Careddu A, Fazi F, Padula F, Fiorini R, Spiriti MA, Petti MC, Venditti A, Amadori S, Mandelli F, Pelicci PG and Nervi C: Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res 66: 8903-8911, 2006.
61. Marks PA and Breslow R: Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25: 84-90, 2007.
62. Roy CC, Kien CL, Bouthillier L and Levy E: Short-chain fatty acids: ready for prime time? Nutr Clin Pract 21: 351-366, 2006.
63. Yoshida M, Matsuyama A, Komatsu Y and Nishino N: From discovery to the coming generation of histone deacetylase inhibitors. Curr Med Chem 10: 2351-2358, 2003.
64. Emanuele S, D'Anneo A, Bellavia G, Vassallo B, Lauricella M, De Blasio A, Vento R and Tesoriere G: Sodium butyrate induces apoptosis in human hepatoma cells by a mitochondria/caspase pathway, associated with degradation of beta-catenin, pRb and Bcl-XL. Eur J Cancer 40: 1441-1452, 2004.
65. Archer SY, Meng S, Shei A and Hodin RA: p21WAF1 is required for butyrate mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 95: 6791-6796, 1998.
66. Demary K, Wong L and Spanjaard RA: Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells. Cancer Lett 163: 103-107, 2001.
67. Melchior SW, Brown LG, Figg WD, Quinn JE, Santucci RA, Brunner J, Thüroff JW, Lange PH and Vessella RL: Effects of phenylbutyrate on proliferation and apoptosis in human cancer cells in vitro and in vivo. Int J Oncol 14: 501-508, 1999.
68. Svechnikova I, Gray SG, Kundrotiene J, Ponthan F, Kogner P and Ekström TJ: Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate. Int J Oncol 22: 579-588, 2003.
69. Su J, He L, Zhang N and Ho PC: Evaluation of tributyrin lipid emulsion with affinity to low-density lipoprotein: pharmacokinetics in adult male Wistar rats and cellular activity on Caco-2 and HepG2 cell lines. J Pharmacol Exp Ther 316: 62-70, 2006.
70. Kuefer R, Hofer MD, Altug V, Zorn C, Genze F, Kunzi-Rapp K, Hautmann RE and Gschwend JE: Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer 26: 535-541, 2004.
71. Marks P: Discovery and development of SAHA as an anticancer agent. Oncogene 26: 1351-1356, 2007.
72. Grant S, Easley C and Kirkpatrick P: Vorinostat. Nat Rev Drug Discov 6: 21-22, 2007.
73. Kelly WK and Marks PA: Drug insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 3: 150-157, 2005.
74. Richon VM: Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br J Cancer 95 (Suppl 1): 2-6, 2006.
75. Marks PA and Dokmanovic M: Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 14: 1497-1511, 2005.
76. Garber K: HDAC inhibitors overcome first hurdle. Nat Biotechnol 25: 17-19: 2007.
77. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H and Richon VM: Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 10: 3923-3931, 2005.
78. Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM and Munster PN: Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 15: 223-237, 2004.
79. Emanuele S, Lauricella M, Carlisi D, Vassallo B, D'Anneo A, Di Fazio P, Vento R and Tesoriere G: SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis 12: 1327-1338, 2007.
80. Pei XY, Dai Y and Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 10: 3839-3852, 2004.
81. + cells sensitive and resistant to STI571. Blood 102: 3765-3774, 2003.
82. Drexler HC and Euler M: Synergistic apoptosis induction by proteasome and histone deacetylase inhibitors is dependent on protein synthesis. Apoptosis 10: 743-758, 2005.
83. Fandy TE, Shankar S, Ross DD, Sausville E and Srivastava RK: Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 7: 646-657, 2005.
84. Nimmanapalli R, Fuino L, Sobaugh C, Richon V and Balla K: Cotreatment with the histone dacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl positive human acute leukaemia cells. Blood 101: 8236-8239, 2003.
85. Takai N, Ueda T, Nishida M, Nasu K and Narahara H: A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells. Int J Mol Med 17: 323-329, 2006.
86. Pathil A, Armeanu S, Venturelli S, Mascagni P, Weiss TS, Gregor M, Lauer UM and Bitzer M: HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology 43: 425-434, 2006.
87. Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, Pagani P, Modena D, Moras ML, Pozzi P, Reznikov LL, Siegmund B, Fantuzzi G, Dinarello CA and Mascagni P: The histone deacetylase inhibitor ITF2357 reduces production of proinflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 11: 1-15, 2005.
88. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S, Kantarjian H, Dugan M, Albitar M and Bhalla K: A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 12: 4628-4635, 2006.
89. Maiso P, Carvajal-Vergara X, Ocio EM, López-Pérez R, Mateo G, Gutiérrez N, Atadja P, Pandiella A and San Miguel JF: The histone deacetylase inhibitor LBH589 is a potent anti-myeloma agent that overcomes drug resistance. Cancer Res 66: 5781-5789, 2006.
90. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T and Nakanishi O: A synthetic inhibitor of histone deacetylase, MS-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 96: 4592-4597, 1999.
91. Nemunaitis JJ, Orr D, Eager R, Cunningham CC, Williams A, Mennel R, Grove W and Olson S: Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer. Cancer J 9: 58-66, 2003.
92. Prakash S, Foster BJ, Meyer M, Wozniak A, Heilbrun LK, Flaherty L, Zalupski M, Radulovic L, Valdivieso M and LoRusso PM: Chronic oral administration of CI-994: a phase 1 study. Invest New Drugs 19: 1-11, 2001.
93. Minucci S and Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51, 2006.
94. Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA and Richon VM: The histone deacetylase inhibitor SAHA arrests cancer cell growth, upregulates thioredoxin: Proc Natl Acad Sci USA 99: 11700-11705, 2002.
95. Xu W, Ngo L, Perez G, Dokmanovic M and Marks PA: Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci USA 103: 15540-15545, 2006.
96. Burgess AJ, Pavey S, Warrener R, Hunte, LJ, Piva TJ, Musgrove EA, Saunders N, Parsons PG and Gabrielli BG: Upregulation of p21WAF1/CIP1 by histone deacetylase inhibitors reduces their cytotoxicity. Mol Pharmacol 60: 828-837, 2001.
97. Archer SY, Johnson J, Kim HJ, Ma Q, Mou H, Daesety V, Meng S and Hodin RA: The histone deacetylase inhibitor butyrate downregulates cyclin B1 gene expression via a p21/WAF-1-dependent mechanism in human colon cancer cells. Am J Physiol Gastrointest Liver Physiol 289: 696-703, 2005.
98. Yokota T, Matsuzaki Y and Sakai T: Trichostatin A activates p18INK4c gene: differential activation and cooperation with p19INK4d gene. FEBS Lett 574: 171-175, 2004.
99. Chen CS, Weng SC, Tseng PH, Lin HP and Chen CS: Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 280: 38879-38887, 2005.
100. Roy S, Packman K, Jeffrey R and Tenniswood M: Histone acetylase inhibitors differentially stabilize p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ 12: 482-491, 2005.
101. Luo J, Su F, Chen D, Shiloh A and Gu W: Deacetylation of p53 modulates its effects on cell growth and apoptosis. Nature 408: 377-381, 2000.
102. Carlisi D, Vassallo B, Lauricella M, Emanuele S, D'Anneo A, Di Leonardo E, Di Fazio P, Vento R and Tesoriere G: Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects. Int J Oncol 32: 177-184, 2008.
103. Kwon HJ, Kim MS, Kim MJ, Nakajima H and Kim KW: Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer 97: 290-296, 2002.
104. Johnstone RW and Licht JD: Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target? Cancer Cell 4: 13-18, 2003.
105. Takada Y, Gillenwater A, Ichikawa H and Aggarwal BB: Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 281: 5612-5622, 2006.
106. Young DA, Lakey RL, Pennington CJ, Jones D, Kevorkian L, Edwards DR, Cawston TE and Clark IM: Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption. Arthritis Res Ther 7: R503-R512, 2005.
107. Vinodhkumar R, Song YS, Ravikumar V, Ramakrishnan G and Devaki T: Depsipeptide a histone deacetlyase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549). Chem Biol Interact 20: 220-229, 2007.
108. Reddy RM, Yeow WS, Chua A, Nguyen DM, Baras A, Ziauddin MF, Shamimi-Noori SM, Maxhimer JB, Schrump DS and Nguyen DM: Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade. Apoptosis 12: 55-71, 2007.
109. Brusilow SW, Danney M, Waber LJ, Batshaw M, Burton B, Levitsky L, Roth K, McKeethren C and Ward J: Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. N Engl J Med 310: 1630-1634, 1984.
110. Perrine SP, Ginder GD, Faller DV, Dover GH, Ikuta T, Witkowska HE, Cai SP, Vichinsky EP and Olivieri NF: A short-term trial of butyrate to stimulate fetal-globin-disorders. N Engl J Med 328, 81-86, 1993.
111. Dover GJ, Brusilow S and Charache S: Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 84: 339-343, 1994.
112. Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW and Dover GJ: Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood 85: 43-49, 1995.
113. Kemp S, Wei HM, Lu JF, Braiterman LT, McGuinness MC, Moser AB, Watkins PA and Smith KD: Gene redundancy and pharmacological gene therapy: implication for X-linked adrenoleukodystrophy. Nat Med 4: 1261-1268, 1998.
114. Rubenstein RC and Zeitlin PL: A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in F508-homozygote cystic fibrosis patients. Am J Respir Crit Care Med 157: 484-490, 1998.
115. Chiurazzi P, Pomponi MG, Pietrobono R, Bakker CE, Neri G and Oostra BA: Synergistic effect of histone hyperacetylation and DNA demethylation in the reactivation of the FMR1 gene. Hum Mol Genet 12: 2317-2323, 1999.
116. Van Breemen MS, Wilms EB and Vecht CJ: Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 6: 421-430, 2007.
117. Gore SD and Carducci MA: Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Expert Opin Investig Drugs 9: 2923-2934, 2000.
118. Carducci MA, Gilbert J, Bowling MK, Noe D, Eisenberger MA, Sinibaldi V, Zabelina Y, Chen TL, Grochow LB and Donehower RC: A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 7: 3047-3055, 2001.
119. Gore SD, Weng LJ, Zhai S, Figg WD, Donehower RC, Dover GJ, Grever M, Griffin CA, Grochow LB, Rowinsky EK, Zabalena Y, Hawkins AL, Burks K and Miller CB: Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukaemia. Clin Cancer Res 7: 2330-2339, 2001.
120. Zhou DC, Kim SH, Ding W, Schultz C, Warrell RP Jr and Gallagher RE: Frequent mutations in the ligand-binding domain of PML-RAR alpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood 99: 1356-1363, 2002.
121. Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG and Heinzel T: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978, 2001.
122. Atmaca A, Al-Batran SE, Maurer A, Neumann A, Heinzel T, Hentsch B, Schwarz SE, Hövelmann S, Göttlicher M, Knuth A and Jäger E: Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 97: 177-182, 2007.
123. Blaheta RA, Michaelis M, Driever PH and Cinatl J Jr: Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 25: 383-397, 2005.
124. Shen J, Huang C, Jiang L, Gao F, Wang Z, Zhang Y, Bai J, Zhou H and Chen Q: Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines. Biochem Pharmacol 73: 1901-1909, 2007.
125. Rikiishi H, Shinohara F, Sato T, et al: Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. Int J Oncol 30: 1181-1188, 2007.
126. Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L, Williams S, Wiegmans AP, Dear AE, Scott CL, Pellegrini M, Wei A, Richon VM, Marks PA, Lowe SW, Smyth MJ and Johnstone RW: Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA 104: 8071-8076, 2007.
127. Mann BS, Johnson JR, He K, Sridhara R, Abraham S, Booth BP, Verbois L, Morse DE, Jee JM, Pope S, Harapanhalli RS, Dagher R, Farrell A, Justice R and Pazdur R: Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res 13: 2318-2322, 2007.
128. Lech-Maranda E, Robak E, Korycka A and Robak T: Depsipeptide (FK228) as a novel histone deacetylase inhibitor: mechanism of action and anticancer activity. Mini Rev Med Chem 7: 1062-1069, 2007.
129. Marshall JL, Rizvi N, Kauh J, Dabut W, Figuera M, Kang MH, Figg WD, Wainer I, Chaissang C, Li MZ and Hawkins MJ: A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2: 325-332, 2002.
130. Lo Russo PM, Demchik L, Foster B, et al: Preclinical antitumor activity of CI-994. Invest New Drug 14: 349-356, 1996.